Literature DB >> 32904110

A long-term survival case of unresectable gastric cancer with multidisciplinary therapy including immunotherapy and abscopal effect.

Yuta Kuhara1, Motoki Ninomiya2, Satoshi Hirahara1, Hirofumi Doi1, Shirakawa Kenji1, Kazuhiro Toyota1, Raita Yano1, Hironori Kobayashi1, Yasushi Hashimoto1, Yujiro Yokoyama1, Yoshihiro Sakashita1, Katsunari Miyamoto1.   

Abstract

The prognosis of unresectable gastric cancer remains poor. Multidisciplinary treatment of unresectable gastric cancer is, therefore, thought to be essential for improving patients' outcomes. Here, we report a successful case of multidisciplinary therapy for unresectable gastric cancer. The patient was a 69-year-old woman who was diagnosed with type 2 gastric cancer with remote lymph node metastases and peritoneal dissemination. Although shrinkage of the primary lesion and remote lymph nodes were observed following chemotherapy, we performed distal gastrectomy to deal with continuous bleeding from the primary lesion. Combination therapy with radiation and chemotherapy was effective for multiple metastases in both subclavian lymph nodes and metachronous multiple axillary lymph nodes. Nivolumab combined with radiation therapy also induced regression of remote lymph node metastases, peritoneal dissemination, and adrenal metastasis. Abscopal effects, i.e., shrinkage of the non-irradiated lesions, were also observed. Thus far, the patient has been able to maintain a good quality of life while receiving continued nivolumab therapy. Multidisciplinary therapy including immunotherapy and abscopal effect may improve the quality of life and contribute to long-term survival of patients with unresectable gastric cancer. © The Japan Society of Clinical Oncology 2020.

Entities:  

Keywords:  Abscopal effect; Gastric cancer; Immunotherapy; Nivolumab; Pseudoprogression; Radiation therapy

Year:  2020        PMID: 32904110      PMCID: PMC7450015          DOI: 10.1007/s13691-020-00433-3

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  22 in total

1.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

Authors:  Julie Brahmer; Karen L Reckamp; Paul Baas; Lucio Crinò; Wilfried E E Eberhardt; Elena Poddubskaya; Scott Antonia; Adam Pluzanski; Everett E Vokes; Esther Holgado; David Waterhouse; Neal Ready; Justin Gainor; Osvaldo Arén Frontera; Libor Havel; Martin Steins; Marina C Garassino; Joachim G Aerts; Manuel Domine; Luis Paz-Ares; Martin Reck; Christine Baudelet; Christopher T Harbison; Brian Lestini; David R Spigel
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

2.  Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial.

Authors:  Antonin Levy; Christophe Massard; Jean-Charles Soria; Eric Deutsch
Journal:  Eur J Cancer       Date:  2016-10-17       Impact factor: 9.162

3.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Authors:  Jeffrey S Weber; Sandra P D'Angelo; David Minor; F Stephen Hodi; Ralf Gutzmer; Bart Neyns; Christoph Hoeller; Nikhil I Khushalani; Wilson H Miller; Christopher D Lao; Gerald P Linette; Luc Thomas; Paul Lorigan; Kenneth F Grossmann; Jessica C Hassel; Michele Maio; Mario Sznol; Paolo A Ascierto; Peter Mohr; Bartosz Chmielowski; Alan Bryce; Inge M Svane; Jean-Jacques Grob; Angela M Krackhardt; Christine Horak; Alexandre Lambert; Arvin S Yang; James Larkin
Journal:  Lancet Oncol       Date:  2015-03-18       Impact factor: 41.316

4.  Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors:  Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

5.  A case of gastric cancer with delayed onset of tumor reduction effect by nivolumab therapy.

Authors:  Rika Satoyoshi; Osamu Muto; Akio Masuda; Kei Kotanagi; Takuya Kichiraku; Kazuhiro Kudoh; Toshiya Sawada; Hideaki Miyazawa; Hitoshi Kotanagi
Journal:  Clin J Gastroenterol       Date:  2018-09-11

6.  An abscopal effect in a case of concomitant treatment of locally and peritoneally recurrent gastric cancer using adoptive T-cell immunotherapy and radiotherapy.

Authors:  Hiro Sato; Yoshiyuki Suzuki; Yuya Yoshimoto; Shin-Ei Noda; Kazutoshi Murata; Yosuke Takakusagi; Atsushi Okazaki; Tetsuo Sekihara; Takashi Nakano
Journal:  Clin Case Rep       Date:  2017-02-15

7.  A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2).

Authors:  Ken Kato; Taroh Satoh; Kei Muro; Takaki Yoshikawa; Takao Tamura; Yasuo Hamamoto; Keisho Chin; Keiko Minashi; Masahiro Tsuda; Kensei Yamaguchi; Nozomu Machida; Taito Esaki; Masahiro Goto; Yoshito Komatsu; Takako Eguchi Nakajima; Naotoshi Sugimoto; Kazuhiro Yoshida; Eiji Oki; Tomohiro Nishina; Akihito Tsuji; Hirofumi Fujii; Kenji Kunieda; Soh Saitoh; Yasushi Omuro; Mizutomo Azuma; Yasuo Iwamoto; Keisei Taku; Sachio Fushida; Li-Tzong Chen; Yoon-Koo Kang; Narikazu Boku
Journal:  Gastric Cancer       Date:  2018-12-01       Impact factor: 7.370

8.  Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study.

Authors:  Chihiro Kondoh; Kohei Shitara; Motoo Nomura; Daisuke Takahari; Takashi Ura; Hiroyuki Tachibana; Natsuo Tomita; Takeshi Kodaira; Kei Muro
Journal:  BMC Palliat Care       Date:  2015-08-04       Impact factor: 3.234

Review 9.  Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions.

Authors:  Yifan Wang; Weiye Deng; Nan Li; Shinya Neri; Amrish Sharma; Wen Jiang; Steven H Lin
Journal:  Front Pharmacol       Date:  2018-03-05       Impact factor: 5.810

10.  Immune blockade inhibitors and the radiation abscopal effect in gastrointestinal cancers.

Authors:  Ioannis A Voutsadakis
Journal:  World J Gastrointest Oncol       Date:  2018-09-15
View more
  2 in total

1.  Case Report: Complete Remission of a Patient With Metastatic Gastric Cancer Treated With Nivolumab Combined With Chemotherapy After Palliative Surgery.

Authors:  Peilin Dai; Xi Rao; Xi Zhang; Enming Qiu; Gang Wu; Yu Lin; Sitong Li; Zhou Li; Zhai Cai; Shuai Han
Journal:  Front Immunol       Date:  2022-06-29       Impact factor: 8.786

Review 2.  Lymph Node Involvement in Advanced Gastric Cancer in the Era of Multimodal Treatment-Oncological and Surgical Perspective.

Authors:  Zuzanna Pelc; Magdalena Skórzewska; Karol Rawicz-Pruszyński; Wojciech P Polkowski
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.